• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Catherine Hollingsworth

Catherine Hollingsworth

Articles

ARTICLES

Genentech Rejects Roche Offer, as Biotech's Shares Near $100

Aug. 14, 2008
By Catherine Hollingsworth

Serentis Will Use $20M Series A to Boost Dermatology Pipeline

Aug. 13, 2008
By Catherine Hollingsworth

Doctors Eager to Use First-Line, Singe-Pill Combo

Aug. 11, 2008
By Catherine Hollingsworth
The recent approval of Novartis AG's Diovan/HCT and Exforge as a first-line, single pill combination for high blood pressure represents an approach to treatment that has become standard practice for many physicians - a sign that doctors are likely to embrace this latest product. (BioWorld Financial Watch)
Read More

Acadia Enters $60M Committed Financing While it Cuts Jobs

Aug. 6, 2008
By Catherine Hollingsworth

FDA Approves Cleviprex for Acute Hypertension

Aug. 5, 2008
By Catherine Hollingsworth

MDRNA Obesity Spray Study Shows Disappointing Results

Aug. 4, 2008
By Catherine Hollingsworth

AtheroGenics Riding High in Positive Diabetes Trial

Aug. 1, 2008
By Catherine Hollingsworth

Cytochroma Flush With Cash for Kidney Disease Trials

July 31, 2008
By Catherine Hollingsworth
Cytochroma hopes to advance its three lead products for kidney disease patients, with an infusion of cash from the closing of a C$45 million (US$44 million) Series C financing and C$105 million licensing deal with Japanese drugmaker Mitsubishi Tanabe Pharma Corp. (BioWorld Today)
Read More

Celator Raises $22.5M for CombiPlex Products Pipeline

July 30, 2008
By Catherine Hollingsworth

EpiCept Soars on News of CHMP Recommendation

July 30, 2008
By Catherine Hollingsworth
View All Articles by Catherine Hollingsworth

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for August 12, 2025.
  • NME Digest: Q2 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • Heart, artery with cholesterol, brain

    In Broadway trial, a hopeful tune for Alzheimer’s prevention

    BioWorld
    At the 2025 Alzheimer’s Association International Conference (AAIC), one of the bigger splashes was made by a cardiovascular drug. In a presentation on July 30,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for August 12, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe